• Profile
Close

Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study

Liver International Dec 07, 2019

Asselah T, Pol S, Hezode C, et al. - Researchers performed this partially randomized, open-label multicenter study in France, to assess the safety as well as the effectiveness of elbasvir/grazoprevir given for 8 and 12 weeks in participants with hepatitis C virus (HCV) genotype (GT) 4 infection. Randomization 2:1 of treatment-naive participants with GT4 infection and F0-F2 fibrosis to receive elbasvir (50 mg)/grazoprevir (100 mg) for 8 or 12 weeks was done. Allocation of treatment-naive participants with F3-F4 fibrosis and all treatment-experienced cases (F0-F4) to elbasvir/grazoprevir was done for 12 weeks. Sustained virologic response (SVR) 12 weeks following the completion of treatment was regarded as the primary endpoint. The attainment of SVR by 94% (50/53) and 96% (26/27) of those taking elbasvir/grazoprevir for 8 or 12 weeks, respectively, was noted among treatment-naive participants with F0-F2 fibrosis, with relapse in 4 participants. The achievement of SVR by 95% (35/37) and relapse in 2 cases was reported in the 12-week arm. Overall, elbasvir/grazoprevir 12 weeks was proved efficacious in treatment-experienced people with HCV GT4 infection and those with advanced fibrosis. An 8-week regimen appeared effective for treating treatment-naive people with mild fibrosis.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay